At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
Pemetrexed +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pemetrexed, Carboplatin, and 1 other intervention for Nonsquamous Nonsmall Cell Neoplasm of Lung. Completed, enrolled 82 participants across 45 sites in 5 countries.
Detailed Summary
A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Italy, Spain, United States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartFeb 2015
Primary CompletionApr 2017
TodayJul 2026
First PostedOct 8, 2014
Enrollment StartFeb 1, 2015
Primary CompletionApr 7, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.7 years ago
Interventions
Pemetrexeddrug
Carboplatindrug
demcizumabdrug